AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31415908 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 RA liraglutide (titrated up to 1.8 mg daily for 12 weeks)
Number of subjects: 0
Study 26354385 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term domiciliary oxygen therapy (LTDOT) for more than 15 hours every day with continuous low flow (1-2 L/min) for 3 years
Number of subjects: 54
Study 26354385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional oxygen therapy)
Number of subjects: 54
Study 26051926 — intervention group
Group type: COMPARATOR
Intervention: US patients
Number of subjects: 0
Study 23333143 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day for 9 days
Number of subjects: 160
Study 21529841 — intervention group
Group type: EXPERIMENTAL
Intervention: NFKB1 (g.-24519delATTG) variant
Number of subjects: 271
Study 21529841 — intervention group
Group type: EXPERIMENTAL
Intervention: NFKBIA (g.-1004A>G) variant
Number of subjects: 271
Study 19933718 — intervention group
Group type: EXPERIMENTAL
Intervention: Call method (investigator-initiated direct contact 'opt-out')
Number of subjects: 1000
Study 19933718 — intervention group
Group type: COMPARATOR
Intervention: Click method (provider-initiated electronic 'opt-in' referral)
Number of subjects: 1000
Study 19933718 — intervention group
Group type: COMPARATOR
Intervention: Letter method (provider-mediated 'opt-in' referral letter)
Number of subjects: 1000
Study 17132302 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum/ALM + BCG
Number of subjects: 544
Study 17132302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vaccine diluent)
Number of subjects: 544
Study 15492459 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational exposure to rayon manufacturing chemicals (RMC, containing predominantly carbon disulfide (CS(2)) and minor sulfuric acid)
Number of subjects: 16
Study 15492459 — intervention group
Group type: COMPARATOR
Intervention: Healthy unexposed controls (Chinese)
Number of subjects: 16
Study 15492459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai workers
Number of subjects: 16
Study 15492459 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese workers
Number of subjects: 16
Study 11769967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 11769967 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 9010794 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants (33 total, including small-for-gestational age and appropriate-for-gestational age)
Number of subjects: 52
Study 9010794 — intervention group
Group type: COMPARATOR
Intervention: Fullterm infants (19 total)
Number of subjects: 52
Study 7950226 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen Qi and Kidney Qi Deficiency (SQKQD) group
Number of subjects: 132
Study 7950226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Qi and Yin Deficiency (QYD) group
Number of subjects: 132
Study 7950226 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver Yin and Kidney Yin Deficiency (LYKYD) group
Number of subjects: 132
Study 7950226 — intervention group
Group type: EXPERIMENTAL
Intervention: With-Dampness group
Number of subjects: 132
Study 7950226 — intervention group
Group type: COMPARATOR
Intervention: Without-Dampness group
Number of subjects: 132
Study 3311100 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid blockade
Number of subjects: 538
Study 3311100 — intervention group
Group type: COMPARATOR
Intervention: General (narcotic-relaxant) anaesthesia
Number of subjects: 538
Study 31448488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 32
Study 31448488 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Neuromodulation (PNM)
Number of subjects: 32
Study 31448488 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TENS and PNM
Number of subjects: 32
Study 30130574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine gluconate + Light Activated Disinfection (LAD)
Number of subjects: 76
Study 30130574 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser irradiation (810 nm, 2 W)
Number of subjects: 76
Study 30130574 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinfection protocols (various methods)
Number of subjects: 76
Study 30130574 — intervention group
Group type: EXPERIMENTAL
Intervention: All evaluated methods
Number of subjects: 76
Study 27619015 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard mobilization with physiotherapists
Number of subjects: 30
Study 27619015 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTOmed‐letto® protocol
Number of subjects: 30
Study 27619015 — intervention group
Group type: EXPERIMENTAL
Intervention: Erigo® protocol
Number of subjects: 30
Study 27619015 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 23922010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (HSFA) diet for 12 weeks
Number of subjects: 39
Study 23922010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with placebo (LFHCC) for 12 weeks
Number of subjects: 39
Study 23922010 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long-chain n-3 fatty acids (LFHCC n-3) for 12 weeks
Number of subjects: 39
Study 23922010 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fatty acid (HMUFA) diet for 12 weeks
Number of subjects: 39
Study 22201658 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls from a peer counselor once per week for five weeks beginning within 72 hours postsurgery
Number of subjects: 142
Study 22201658 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls from a peer counselor once weekly for five weeks beginning six weeks postsurgery
Number of subjects: 142
Study 22201658 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls from a peer counselor by request
Number of subjects: 142
Study 22201658 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study 20353612 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer role play (RP)
Number of subjects: 69
Study 20353612 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised patients (SP)
Number of subjects: 69
Study 18694405 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) by Year 6 students
Number of subjects: 131
Study 18694405 — intervention group
Group type: COMPARATOR
Intervention: Qualified tutors (paid doctors)
Number of subjects: 131
Study 15962676 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0
Study 15962676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg)
Number of subjects: 0
Study 15962676 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 0
Study 15962676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12883542 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly supervised exercise training
Number of subjects: 7
Study 12883542 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 months after RCT
Number of subjects: 7
Study 12883542 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between pain and exercise adherence
Number of subjects: 7
Study 10691072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Series (MS)
Number of subjects: 54
Study 10691072 — intervention group
Group type: COMPARATOR
Intervention: Pantomographic Series (PS)
Number of subjects: 54
Study 9496215 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric blanket group (n = 10)
Number of subjects: 18
Study 9496215 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 18
Study 7678043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilutamide
Number of subjects: 457
Study 7678043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study 3753363 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (S) 25 mg orally, four times per day
Number of subjects: 9
Study 3753363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study 29128192 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab 30 mg Q4W
Number of subjects: 83
Study 29128192 — intervention group
Group type: EXPERIMENTAL
Intervention: benralizumab 30 mg Q8W
Number of subjects: 83
Study 29128192 — intervention group
Group type: COMPARATOR
Intervention: placebo Q4W
Number of subjects: 83
Study 27737722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-diet group (improved fat quality diet)
Number of subjects: 115
Study 27737722 — intervention group
Group type: COMPARATOR
Intervention: C-diet group (control diet)
Number of subjects: 115
Study 24628682 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky single-occasion drinking
Number of subjects: 802
Study 24628682 — intervention group
Group type: EXPERIMENTAL
Intervention: Private home drinking
Number of subjects: 802
Study 24628682 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking with friends
Number of subjects: 802
Study 24628682 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of drinking locations
Number of subjects: 802
Study 24047061 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral-sling surgery
Number of subjects: 460
Study 24047061 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 460
Study 20027034 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 149
Study 20027034 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 149
Study 18420764 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum smoking cessation and relapse prevention intervention
Number of subjects: 0
Study 18420764 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15879332 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 1405
Study 15879332 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 1405
Study 12649124 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH55700 1.0 mg/kg
Number of subjects: 32
Study 12649124 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH55700 0.3 mg/kg
Number of subjects: 32
Study 12649124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11194275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (300 mg delayed release for 7 to 9 weeks)
Number of subjects: 0
Study 11194275 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus nicotine patch
Number of subjects: 0
Study 11194275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11194275 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 0
Study 8773551 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative home-health nursing intervention
Number of subjects: 22
Study 8773551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 22
Study 31211375 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted PCOS
Number of subjects: 22406
Study 30561264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (simvastatin + ezetimibe)
Number of subjects: 40
Study 30561264 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 40
Study 30561264 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 30561264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 40
Study 27346837 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention promoting an active lifestyle, based on motivational interviewing
Number of subjects: 39
Study 24408305 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ISU303
Number of subjects: 18
Study 24408305 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg ISU303
Number of subjects: 18
Study 24408305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22115011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg (E)
Number of subjects: 40
Study 22115011 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg (S)
Number of subjects: 40
Study 22115011 — intervention group
Group type: COMPARATOR
Intervention: Combination of ezetimibe/simvastatin 10/20mg (C)
Number of subjects: 40
Study 18207121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 70
Study 18207121 — intervention group
Group type: COMPARATOR
Intervention: Optical penalization with positive lenses
Number of subjects: 70
Study 16504368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (Livial) 2.5 mg/day + Alendronate sodium (Fosamax) 10 mg/day
Number of subjects: 32
Study 16504368 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate sodium (Fosamax) 10 mg/day
Number of subjects: 32
Study 16504368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study 14673681 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sympathetic block (ESB) at T2
Number of subjects: 22
Study 14673681 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sympathetic block (ESB) at T4
Number of subjects: 22
Study 11142075 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Self-Management Programme (ASMP)
Number of subjects: 544
Study 9354202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week triple therapy of omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tetracycline 500 mg b.d. (OCT)
Number of subjects: 153
Study 9354202 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week dual therapy of omeprazole 20 mg b.d. and amoxycillin 1 g b.d. (OA)
Number of subjects: 153
Study 9354202 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with OA regimen after OCT failure
Number of subjects: 153
Study 9354202 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with OCT therapy after OA failure
Number of subjects: 153
Study 9354202 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate for triple and dual therapy sequence
Number of subjects: 153
Study 9354202 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate for dual followed by triple therapy
Number of subjects: 153
Study 8250615 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6‐1.8 mg/day)
Number of subjects: 25
Study 8250615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 8250615 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 25
Study 3457171 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride gel
Number of subjects: 57
Study 3457171 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% stannous fluoride
Number of subjects: 57
Study 3457171 — intervention group
Group type: COMPARATOR
Intervention: 0.05% sodium fluoride solution
Number of subjects: 57
Study 3457171 — intervention group
Group type: COMPARATOR
Intervention: 0.2% sodium fluoride solution
Number of subjects: 57
Study 3457171 — intervention group
Group type: COMPARATOR
Intervention: 2% sodium fluoride solution
Number of subjects: 57
Study 3457171 — intervention group
Group type: COMPARATOR
Intervention: 0.4% stannous fluoride gel
Number of subjects: 57
Study 30390943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal carboplatin (AUC 6) every 3 weeks with intravenous paclitaxel weekly at 80 mg/m2
Number of subjects: 49
Study 30390943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal carboplatin and intravenous paclitaxel
Number of subjects: 49
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Small deep infarct (lacunar)
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian wedge
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical paramedian
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Other
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Old lacunes on T1/fluid-attenuated inversion recovery
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial stenosis ≥50%
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent stroke or death
Number of subjects: 644
Study 26956031 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned treatment
Number of subjects: 644
Study 24127851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics with single-dose i.v. cefazolin (1 g)
Number of subjects: 206
Study 24127851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics with single-dose i.v. ceftriaxone (1 g)
Number of subjects: 206
Study 24127851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics with oral levofloxacin (500 mg)
Number of subjects: 206
Study 24127851 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 206
Study 24127851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (all types)
Number of subjects: 206
Study 22736124 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-antibiotics restriction group
Number of subjects: 64
Study 22736124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation group
Number of subjects: 64
Study 22736124 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative fasting group
Number of subjects: 64
Study 22736124 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic restriction group
Number of subjects: 64
Study 20077053 — intervention group
Group type: EXPERIMENTAL
Intervention: tesofensine
Number of subjects: 62
Study 20077053 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62
Study 18377127 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (10 min)
Number of subjects: 180
Study 18377127 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 180
Study 18377127 — intervention group
Group type: EXPERIMENTAL
Intervention: MET plus cognitive-behavioral therapy (CBT)
Number of subjects: 180
Study 18377127 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 180
Study 16898079 — intervention group
Group type: COMPARATOR
Intervention: r-hIL-18 BP (20, 70, 210 or 350 mg, sc)
Number of subjects: 105
Study 16898079 — intervention group
Group type: COMPARATOR
Intervention: r-hIL-18 BP (35 or 175 mg, sc, 6 injections, 48 h apart)
Number of subjects: 105
Study 16898079 — intervention group
Group type: COMPARATOR
Intervention: r-hIL-18 BP (20, 160 or 320 mg, sc tiw)
Number of subjects: 105
Study 16898079 — intervention group
Group type: COMPARATOR
Intervention: r-hIL-18 BP (20, 80, 160 mg, sc tiw)
Number of subjects: 105
Study 14593351 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (1.25‐10 mg/day)
Number of subjects: 54
Study 14593351 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 10938496 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure for men age < 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Night time ambulatory blood pressure for men age < 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure for women age < 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Night time ambulatory blood pressure for women age < 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure for men age >= 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Night time ambulatory blood pressure for men age >= 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure for women age >= 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Night time ambulatory blood pressure for women age >= 50
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure corresponding to WHO's upper limit for normal blood pressure (clinic)
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Night time ambulatory blood pressure corresponding to WHO's upper limit for normal blood pressure (clinic)
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure corresponding to clinic pressure of 95 mmHg
Number of subjects: 352
Study 8999617 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure corresponding to clinic pressure of 100 mmHg
Number of subjects: 352
Study 1335442 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine during ECC
Number of subjects: 120
Study 1335442 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine before and during ECC
Number of subjects: 120
Study 1335442 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate
Number of subjects: 120
Study 6373679 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 6373679 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 12
Study 29685023 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Number of subjects: 30
Study 29685023 — intervention group
Group type: COMPARATOR
Intervention: Control group (rehabilitative exercises)
Number of subjects: 30
Study 27274213 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification through a small pupil using minimal iris manipulation
Number of subjects: 123
Study 27274213 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification through a well-dilated pupil
Number of subjects: 123
Study 27274213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123